# Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

> **NCT00203021** · PHASE4 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 208 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer acetate

## Key facts

- **NCT ID:** NCT00203021
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-03-26
- **Primary completion:** 2018-02-28
- **Final completion:** 2018-02-28
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2020-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203021, "Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00203021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*